A Randomized Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab Compared to Paclitaxel/Trastuzumab/Pertuzumab/Pembrolizumab in First-Line HER2-Positive Metastatic Breast Cancer

Trial Profile

A Randomized Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab Compared to Paclitaxel/Trastuzumab/Pertuzumab/Pembrolizumab in First-Line HER2-Positive Metastatic Breast Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top